Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control

Robert Schnoll^{1

2}, Justin E Bekelman^{2

3}, Daniel Blumenthal¹, David A Asch⁴, Alison M Buttenheim⁵, Krisda H Chaiyachati⁶, Susan M Domchek^{2

4

7}, Oluwadamilola M Fayanju^{2

3

8}, Peter Gabriel^{2

3}, Brian P Jenssen⁹, Frank T Leone¹⁰, Anne Marie McCarthy^{2

3

11}, Katherine L Nathanson^{2

4

7}, Ravi B Parikh^{2

3

4}, Katharine A Rendle^{2

3

11

12}, Rachel C Shelton¹³, Lawrence N Shulman^{2

3}, Samuel U Takvorian^{2

3

4}, Susan Ware¹, E Paul Wileyto¹¹, Rinad S Beidas¹⁴

Affiliations

¹ Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
² Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
³ Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, USA.
⁴ Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
⁵ Department of Family and Community Health, School of Nursing, University of Pennsylvania, Philadelphia, USA.
⁶ Verily Life Sciences, South San Francisco, CA.
⁷ Basser Center for BRCA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
⁸ Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
⁹ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
¹⁰ Pulmonary, Allergy & Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
¹¹ Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
¹² Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
¹³ Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, USA.
¹⁴ Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, USA.

PMID: 39619072
PMCID: PMC11604509
DOI: 10.1017/cts.2024.554

Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control

Robert Schnoll et al. J Clin Transl Sci. 2024.

. 2024 Oct 16;8(1):e166.

doi: 10.1017/cts.2024.554. eCollection 2024.

Authors

Affiliations

¹ Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
² Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
³ Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, USA.
⁴ Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
⁵ Department of Family and Community Health, School of Nursing, University of Pennsylvania, Philadelphia, USA.
⁶ Verily Life Sciences, South San Francisco, CA.
⁷ Basser Center for BRCA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
⁸ Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
⁹ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
¹⁰ Pulmonary, Allergy & Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
¹¹ Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
¹² Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
¹³ Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, USA.
¹⁴ Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, USA.

PMID: 39619072
PMCID: PMC11604509
DOI: 10.1017/cts.2024.554

Abstract

Traditional approaches for evaluating the impact of scientific research - mainly scholarship (i.e., publications, presentations) and grant funding - fail to capture the full extent of contributions that come from larger scientific initiatives. The Translational Science Benefits Model (TSBM) was developed to support more comprehensive evaluations of scientific endeavors, especially research designed to translate scientific discoveries into innovations in clinical or public health practice and policy-level changes. Here, we present the domains of the TSBM, including how it was expanded by researchers within the Implementation Science Centers in Cancer Control (ISC3) program supported by the National Cancer Institute. Next, we describe five studies supported by the Penn ISC3, each focused on testing implementation strategies informed by behavioral economics to reduce key practice gaps in the context of cancer care and identify how each study yields broader impacts consistent with TSBM domains. These indicators include Capacity Building, Methods Development (within the Implementation Field) and Rapid Cycle Approaches, implementing Software Technologies, and improving Health Care Delivery and Health Care Accessibility. The examples highlighted here can help guide other similar scientific initiatives to conceive and measure broader scientific impact to fully articulate the translation and effects of their work at the population level.

Keywords: Translational Science Benefits Model; behavioral economics; cancer; impact; implementation science.

PubMed Disclaimer

Conflict of interest statement

Justin E. Bekelman reports grants from AstraZeneca, Emerson Collective, Loxo@Lilly, and Gilead and personal fees from Reimagine Care, Healthcare Foundry, and AstraZeneca, outside the submitted work. David A. Asch is a partner at VAL Health and has received grants from UnitedHealth Group and personal fees from Deloitte, MARS Veterinary Group, and Boehringer Ingelheim. Krisda H. Chaiyachati reports employment and equity ownership in Verily Life Sciences; honoraria from the Robert Wood Johnson Foundation; and is on the board of directors for the American Board of Internal Medicine and Intend Health Strategies. Susan M. Domchek reports consulting fees from AstraZeneca and GlaxoSmithKline. Oluwadamilola M. Fayanju reports grants paid to her institution from Gilead, Inc. outside the submitted work. Katherine L. Nathanson reports serving on a Scientific Advisory Board for Merck, unrelated to the current study. Katharine A. Rendle reports receiving grants from Pfizer and AstraZeneca paid to her institution, personal fees from Merck for serving as a scientific consultant, and honoraria and travel paid as an invited speaker from MJH Life Sciences outside the submitted work. Rinad S. Beidas is the principal at Implementation Science & Practice, LLC. She has received royalties from Oxford University Press, consulting fees from United Behavioral Health and OptumLabs, and serves on the advisory boards for AIM Youth Mental Health Foundation and the Klingenstein Third Generation Foundation. She also currently serves on the National Advisory Mental Health Council and NASEM Blueprint for a National Prevention Infrastructure for Behavioral Health Disorders study outside of the submitted work.

Figures

**Figure 1.**
Tobacco use treatment clinician-directed nudge.

**Figure 2.**
Patient-directed nudge to promote engagement with serious illness conversations.

See this image and copyright information in PMC

References

1. Maddox BB, Phan ML, Byeon YV, et al. Metrics to evaluate implementation scientists in the USA: what matters most? Implement Sci Commun. 2022;3 ( 1 ):75. doi: 10.1186/s43058-022-00323-0. - DOI - PMC - PubMed
1. Luke DA, Sarli CC, Suiter AM, et al. The translational science benefits model: a new framework for assessing the health and societal benefits of clinical and translational sciences. Clin Transl Sci. 2018;11 ( 1 ):77–84. doi: 10.1111/cts12495. - DOI - PMC - PubMed
1. Committee to Review the Clinical and Translational Science Awards Program at the National Center for Advancing Translational Sciences, Board on Health Sciences Policy, Institute of Medicine. Leshner AI, Terry SF, Schultz AM, Liverman CT, eds. The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research. National Academies Press; 2013. - PubMed
1. Oh AY, Emmons KM, Brownson RC, et al. Speeding implementation in cancer: The National Cancer Institute’s Implementation Science Centers in Cancer Control. J Natl Cancer Inst. 2023;8 ( 2 ):131–138. doi: 10.1093/jnci/djac198. - DOI - PMC - PubMed
1. Oh A, Vinson CA, Chambers DA. Future directions for implementation science at the National Cancer Institute: Implementation Science Centers in Cancer Control. Transl Behav Med. 2021;16 ( 2 ):669–675. doi: 10.1093/tbm/ibaa018. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control

Affiliations

Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources